Introduction
============

Acute kidney injury (AKI) is a severe perioperative complication.[@b1-clep-10-1583],[@b2-clep-10-1583] Although the incidence of postsurgical AKI depends immensely on the type of the surgery, up to 40% of hospital-acquired AKI is related to the perioperative setting.[@b3-clep-10-1583],[@b4-clep-10-1583] It is associated with prolonged hospital stay, increased costs, and both short- and long-term mortality.[@b5-clep-10-1583]--[@b8-clep-10-1583] Among the patients with the most severe forms of AKI, those requiring dialysis (AKI-D) experience higher mortality[@b9-clep-10-1583] and incur greater resource use.[@b10-clep-10-1583],[@b11-clep-10-1583] Additionally, postsurgical AKI is associated with long-term adverse events including mortality and the development of chronic kidney disease.[@b12-clep-10-1583]--[@b14-clep-10-1583] AKI can be a reflection of the general insult of critical illness while also being an independent contributor to that illness; postsurgical AKI is of particular interest as a significant and measurable event of perioperative harm and a plausible target for intervention. Severe AKI after a major surgery is associated with a high risk of mortality and increased costs of care; this adverse impact might extend beyond the discharge of such surgical patients from the hospital.[@b15-clep-10-1583]

Recently, the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP)[@b16-clep-10-1583] was established based on a "surgery-target" approach for improving risk-adjusted surgical outcomes and allowing highly detailed evaluations of performance and zero in on preventable complications.[@b17-clep-10-1583],[@b18-clep-10-1583] Because a growing movement aims to tie reimbursements to outcomes, the performance related to the influence of postsurgical AKI among different surgeries to in-hospital, 30-day, and long-term mortality as well as dialysis dependence is important for enhancing quality initiatives. To our knowledge, the association between surgical type and 30-day or long-term dialysis dependence together with the clinical significance of AKI episodes with respect to clinically relevant outcomes has not been comprehensively studied in a surgical patient population.

This study aimed to evaluate the influence of AKI-D on postsurgical in-hospital, 30-day, and long-term outcomes, including mortality and dialysis dependence, among patients who were undergoing different major surgeries. We investigated the association between AKI-D and outcomes while adjusting for surgery procedures, patient demographics, and comorbidities, using a large nationwide database and validated by prospectively enrolled nationwide cohort.

Methods
=======

Data source
-----------

The National Health Insurance Research Database (NHIRD) of the National Health Insurance (NHI) program is mandatory and universal, offering comprehensive medical care coverage to more than 99% of the country's population of 23 million people. The NHI system contains all original claims data, including demographic information and detailed orders, for all clinic visits and hospitalizations. Disease diagnoses for all individuals are classified according to the ICD, Ninth Revision, Clinical Modification (ICD-9-CM). Taiwan's NHI records are regularly inspected, and physicians who violate the standards of clinical practice are subject to financial penalties.[@b19-clep-10-1583] The accuracy of diagnoses registered in the NHIRD has been validated.[@b20-clep-10-1583],[@b21-clep-10-1583]

For this study, patients (aged ≥18 years) who were admitted to the hospital from January 2001 to December 2007 for major surgery and who developed AKI-D during their index admission were identified in the NHI databases. Surgical procedures were considered major if the length of the intensive care unit (ICU) stay for patients in a given diagnosis-related group exceeded 2 days.[@b22-clep-10-1583] Major surgery procedures were further classified into cardiothoracic, esophageal, intestinal, and hepatic as the primary diagnosis codes.[@b4-clep-10-1583] We further divided all major surgeries into cardiothoracic surgery (CTS) and non-CTS. Because the identification numbers of all individuals in the NHRID were encrypted to protect the privacy of the individuals and informed consent was waived due to the secondary nature of the patient data, this study underwent limited ethical review by the Institutional Review Board of National Taiwan University Hospital (approval reference no. 201212021RINC).

Validation cohort
-----------------

The Taiwan Consortium for Acute Kidney Injury and Renal Diseases (CAKS) from the National Research Program for Biopharmaceuticals has launched a nationwide epidemiology and prognostic program for tracking AKI-D, which prospectively enrolls critically ill patients with AKI-D in ICUs. CAKS includes 30-member hospitals that are widely distributed throughout the four geographical regions (north, middle, south, and east) of Taiwan. The CAKS member hospitals have a 1:1 ratio of medical centers to regional hospitals in each region and in the four seasonally sampled months (October 2014 and January, April, and July 2015).[@b23-clep-10-1583] Patients undergoing dialysis after major surgery were selected to be in the validation cohort. This cohort included 79 CTS patients and 154 non-CTS patients. We used this cohort to validate different clinical manifestations and laboratory data between CTS patients and non-CTS patients during AKI-D. Detailed laboratory data and scoring systems were compared in each group of patients at ICU admission and the initiation of renal replacement therapy (RRT).

Data collection and outcome measures
------------------------------------

Patient demographics, surgery type, Charlson comorbidity index, comorbidities before admission, and postsurgical outcomes including the in-hospital, 30-day, and long-term mortality together with dialysis dependence were reviewed from the database. The primary outcomes were in-hospital, 30-day, and long-term mortality after hospital discharge. The secondary outcomes were 30-day and long-term dialysis dependence defined as the requirement for dialysis for at least 3 months after hospital discharge, with mortality treated as a competing risk. Composite outcomes combined the outcomes of mortality and dialysis dependence. Each patient was monitored from the date of discharge to 30 days after discharge for 30-day mortality and was censored at either death or the end of the study (December 31, 2010) for long-term outcome, whichever occurred first.

Statistical analyses
--------------------

We followed the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) recommendations for this study. After discharge, the status of dialysis dependence was integrated as a time-varying risk.

We performed a propensity score matching (PSM) to reduce the selection bias due to the baseline differences between the patients of AKI with dialysis and those of AKI without dialysis. First, we conducted multivariate logistic regression analysis to identify the predictors for the prescription of dialysis. Using logistic regression model, factors during the index hospitalization as predictors of AKI-D including age, sex, surgical type, hospital stay length, Charlson comorbidity index score, comorbidities, and postsurgical complications were identified as parameters for further PSM ([Table S1](#SD3-clep-10-1583){ref-type="supplementary-material"} and [Figures S2](#SD2-clep-10-1583){ref-type="supplementary-material"}). Then, we used the "Match()" function in the "Matching" library of the R statistical software to do PSM based on the default value of "caliper" (ie, caliper = 0.25) and the Mahalanobis distance without replacement. After the matching, the standardized mean difference of all variables was \<0.1 ([Figure S2](#SD2-clep-10-1583){ref-type="supplementary-material"}).

Patients who did not undergo acute dialysis during their index hospitalization but had a major surgery were matched to the study group at a 1:4 ratio after matching for age, sex, Charlson comorbidity index, and propensity score. We first modeled 30-day and long-term mortality using the occurrence of AKI-D after the surgery as the primary covariate of interest and adjusted for surgery type and preoperative covariates, including age, sex, Charlson comorbidity index, and individual comorbidities. However, cardiac surgery had the highest postoperative AKI risk.[@b24-clep-10-1583] In addition, acute renal failure after cardiac surgery is known to be associated with significant short-term morbidity and mortality.[@b25-clep-10-1583] In light of this, we constructed a second model stratifying AKI-D patients into CTS and non-CTS while adjusting the same preoperative covariates as the first model. In further parametric modeling with regard to factors associated with outcome, we adopted three modeling methods: simple Cox regression, multivariable Cox regression, and the competing risk regression. A Cox proportional regression model was used to calculate the adjusted hazard ratios (aHRs) and 95% CIs for the outcomes including in-hospital, 30-day, and long-term mortality and dialysis dependence. Because of high mortality and dialysis dependence rates in surgical patients with AKI-D, competing risk regression applying Fine and Gray modeling for consideration of the subdistribution hazard was performed to model dialysis dependence while treating mortality as a competing risk.[@b26-clep-10-1583] Furthermore, the validation cohort was analyzed by PSM at a 1:1 ratio after matching for comorbidities and baseline demographics including age, sex, and severity scores. A bivariate analysis was performed using the *t*-test for normally distributed continuous variables and Wilcoxon rank-sum test for non-normally distributed continuous variables, and a chi-squared analysis was used for categorical variable comparisons and outcome events. Missing or invalid data on age, sex, and related variables were noted in 1.2% of the patients, and these patients were excluded from the analyses. We used R software, version 2.8.1 (Free Software Foundation, Inc., Boston, MA, USA); competing risk analysis was performed with Stata MP, version 12 (StataCorp, College Station, TX, USA). A two-sided *P*-value \<0.05 was considered statistically significant.

Results
=======

Data source and participants
----------------------------

From 2001 to 2007, 112,745 patients underwent major surgeries and 1,861 surgical patients with AKI-D during their index hospitalization were enrolled in the study ([Figure 1](#f1-clep-10-1583){ref-type="fig"}). The incidence of AKI-D after major surgeries increased during this period, and the aHR of 30-day and long-term mortality also increased simultaneously ([Figure S1](#SD1-clep-10-1583){ref-type="supplementary-material"} and [Table S2](#SD4-clep-10-1583){ref-type="supplementary-material"}). Compared with all the risk factors, AKI-D was the top risk factor for 30-day and long-term mortality ([Table S3](#SD5-clep-10-1583){ref-type="supplementary-material"}). With PSM at a 1:4 ratio, 8,320 surgical patients, 1,664 with AKI-D and 6,656 without dialysis were further analyzed.

Demographic characteristics, comorbidities, postsurgical complications, and outcomes
------------------------------------------------------------------------------------

Baseline characteristics stratified by the AKI-D, surgery type, and comorbidities before and after the PSM are presented in [Table 1](#t1-clep-10-1583){ref-type="table"}. Of all patients undergoing major surgeries, the AKI-D group had the most underlying diseases and postsurgical comorbidities compared with the non-AKI-D group ([Table 1](#t1-clep-10-1583){ref-type="table"}). Besides, the surgical patients with AKI-D had higher in-hospital mortality compared with the non-AKI-D surgical patients (66.95% vs 5.37%). After the PSM ([Table S1](#SD3-clep-10-1583){ref-type="supplementary-material"} and [Figures S2](#SD2-clep-10-1583){ref-type="supplementary-material"}), the surgical patients with AKI-D still had higher in-hospital mortality compared with the non-AKI-D surgical patients (68·87% vs 22·64%).

All-cause mortality after postsurgical AKI-D
--------------------------------------------

After PSM, 8,320 surgical patients were analyzed using time-dependent Cox proportional hazard modeling, with dialysis dependence after hospital discharge as the time-varying risk. Similar results were obtained before and after PSM. After matching with the adjustment of baseline demographics, surgery type, Charlson comorbidity index, and comorbidities, postsurgical AKI-D augmented in-hospital (aHR: 3.04, 95% CI 2.79--3.31), 30-day (aHR: 3.65, 95% CI 3.37--3.94), and long-term (aHR: 3.22, 95% CI 3.01--3.44) mortality after a median follow-up of 294.5 days ([Table 2](#t2-clep-10-1583){ref-type="table"}).

Competing risk models of the outcomes
-------------------------------------

The competing risk model for stratifying AKI-D patients into CTS and non-CTS patients was additionally adjusted for age, sex, Charlson comorbidity index, individual comorbidities, and propensity score. We found similar results before and after PSM. After the matching, patients who underwent CTS had lower in-hospital (aHR: 0.85, 95% CI 0.75--0.97), 30-day (aHR: 0.79, 95% CI 0.70--0.89), and long-term mortality (aHR: 0.80, 95% CI 0.72--0.90); higher 30-day dialysis dependence (competing subhazard ratio \[sHR\]: 1.67, 95% CI 1.18--2.38); and similar long-term dialysis dependence (sHR: 1.38, 95% CI 0.96--2.00) compared with non-CTS patients after accounting for mortality as a competing risk ([Table 3](#t3-clep-10-1583){ref-type="table"} and [Figure 2](#f2-clep-10-1583){ref-type="fig"}). Furthermore, CTS patients had better 30-day (aHR: 0.85, 95% CI 0.76--0.96) and long-term (aHR: 0.81, 95% CI 0.73--0.91) composite outcome than non-CTS patients ([Table 3](#t3-clep-10-1583){ref-type="table"}).

Clinical manifestations of postsurgical AKI
-------------------------------------------

More detailed laboratory data of CTS and non-CTS patients were compared across all hospitals in the CAKS cohort[@b23-clep-10-1583] for the validation of different clinical manifestations at postsurgical AKI during hospitalization. After PSM at a 1:1 ratio ([Table S4](#SD6-clep-10-1583){ref-type="supplementary-material"}), 144 patients (72 CTS patients, 72 non-CTS patients) were further analyzed. Non-CTS patients had more comorbidities of sepsis and azotemia during index hospitalization, together with more hypoalbuminemia and more metabolic acidosis compared with CTS patients ([Table 4](#t4-clep-10-1583){ref-type="table"}). Furthermore, non-CTS patients tend to receive intermittent hemodialysis, while CTS patients tend to receive continuous venovenous hemofiltration during acute kidney injury requiring dialysis ([Table 4](#t4-clep-10-1583){ref-type="table"}).

Discussion
==========

Postsurgical AKI-D was associated with in-hospital, 30-day, and long-term mortality in patients undergoing major surgeries. In the analysis of surgery type, AKI-D patients who underwent CTS had lower in-hospital, 30-day, and long-term mortality compared with patients who had other types of surgeries. However, CTS patients with AKI-D had a higher risk of 30-day dialysis dependence but a similar risk of long-term dialysis dependence compared with non-CTS patients. This study showed that AKI-D in CTS and non-CTS patients had different clinical manifestation, mortality, and dialysis dependence patterns during hospitalization and even after hospital discharge, and thus should have different multidisciplinary teams to facilitate the implementation of enhanced recovery pathways.[@b27-clep-10-1583] Because the incidence of AKI-D after major surgeries has increased in recent years,[@b28-clep-10-1583] these findings provide a future direction of study for solving the unmet need of improving the mortality and outcomes in patients undergoing major surgeries with AKI-D. Furthermore, these results have significant implications for considering prevention strategies regarding different pathophysiology in the perioperative care of the patient undergoing major surgeries who has AKI-D.

In a study using data from the Ontario, Canada, universal health care databases to examine consecutive patients who had major elective surgery between 1995 and 2009, the incidence of AKI-D increased from 0.2% in 1995 to 0.6% in 2009 while 42% died within 90 days of surgery with no change in 90-day survival overtime and no change in chronic dialysis overtime among the patients surviving beyond 90 days.[@b29-clep-10-1583] Lenihan et al examined AKI-D trends in a nationwide inpatient sample of individuals 75 years or older admitted for cardiac surgery. They found that the risk of AKI-D was significantly higher in 2008 than in 1999 (OR, 2.23; 95% CI 1.78--2.80), and the attributable risks for in-hospital mortality associated with AKI-D increased from 5% in 1999 to 14% in 2008.[@b30-clep-10-1583] Compared with these studies, we studied longer-term outcomes than in-hospital or 90-day mortality and found an increased chance of post-surgical AKI-D together with increased long-term mortality overtime.[@b29-clep-10-1583],[@b30-clep-10-1583] The growing incidence of AKI-D may be due to a heightened awareness and better detection of AKI with the introduction of the RIFLE (risk, injury, failure, loss, end-stage renal disease) criteria in 2003[@b31-clep-10-1583] and the AKIN (acute kidney injury network) criteria[@b32-clep-10-1583] for AKI or the postsurgical cooperation of new RRT technology such as continuous RRT. However, even with adjustment for the higher burden of comorbid conditions and complications, the hazard ratio for mortality increased over the years, and this may be due to the shift toward more complex and higher risk procedures on sicker patients.[@b33-clep-10-1583]

The novel finding of our study is that post-CTS patients with AKI-D have lower in-hospital, 30-day, and long-term mortality than non-CTS patients. This finding fills important gaps in previous research. Because AKI-D is a perilous postsurgical complication associated with increased risk of mortality, dialysis dependence, resource utilization, and cost,[@b8-clep-10-1583],[@b34-clep-10-1583] action is urgently required to increase awareness of and to prevent AKI in patients undergoing different major surgeries and to facilitate renal recovery as early as possible to decrease mortality. Our study extends this finding by providing an overview of all surgical patients including CTS and non-CTS patients with the most severe form of AKI, AKI-D. CTS increases the likelihood of ischemia--reperfusion injury that temporarily compromises renal perfusion and causes renal dysfunction,[@b35-clep-10-1583] the so-called cardiorenal syndrome type 1 in which patients are more likely to be weaned from dialysis.[@b36-clep-10-1583] Additionally, our study confirms recent findings that a substantial percentage of AKI-D survivors stay dialysis-dependent after the acute phase of their illness has resolved.[@b37-clep-10-1583],[@b38-clep-10-1583] Even with lower mortality in CTS patients, this finding serves as an impetus to develop greatly needed measures that protect and restore kidney function as soon as possible after AKI-D.

This study provides updated evidence of the epidemiology of AKI in surgical patients together with mortality and dialysis dependence data, which is the missing puzzle piece for the quality control of surgical efficacy and performance in public health. Moreover, the results support the renal angina concept that AKI can be stratified into different surgery type categories.[@b39-clep-10-1583],[@b40-clep-10-1583] Efforts of hemodynamic manipulations and close attention to intravenous resuscitation strategies including goal-directed therapy cannot be neglected to reduce AKI following major surgeries and its influence on postsurgical complications.[@b41-clep-10-1583]

These results provide direction for more personalized evaluation and optimized follow-up, taking into account surgery-specific characteristics. These findings also reinforce the importance of perioperative risk stratification for kidney injury and the implementation of strategies available to help prevent postsurgical AKI and long-term dialysis dependence. Furthermore, the findings indicate the potential for therapeutic interventions to attenuate the high burden of death and dialysis dependence after postsurgical AKI has occurred.

Strengths and limitations
-------------------------

A major strength of this study is the use of a large nationally representative database with exceptionally long renal followup; this gives us the ability to generalize and extrapolate the data with greater confidence. The NHIRD data are trustworthy because the database undergoes periodic detailed medical chart reviews and medical charge audits by professionals.[@b42-clep-10-1583] The main limitation of our study is the lack of laboratory results for the national administrative dataset, leading to the possibility of residual confounding. Stricter control for estimated glomerular filtration rate or chronic kidney disease stage is crucial to derive more meaningful information. Besides, the CAKS database only included patients from ICU and that might bias our finding. Nevertheless, we validated the results in a different database with detailed laboratory data, and the results were similar in proving different manifestations in CTS and non-CTS patients in AKI. Furthermore, because this study was a retrospective observational analysis, a causal inference could not be derived. We did not assess the effect of the hospital- and surgeon-related factors such as hospital volume, location, emergent or elective surgery, prescribing physician, and level of experience. For the avoidance of the clustering effect, we used PSM together with multivariate adjustments and evaluated the model discrimination; we also attempted to increase the internal validity by using competing risk models.[@b43-clep-10-1583],[@b44-clep-10-1583] Because a high percentage of patients die after surgical AKI, we used competing risk analysis to examine the potential long-term dialysis dependence that would avoid confounding due to the "Will Rogers effect" of stage migration.[@b45-clep-10-1583] Ours is also the first study to provide valuable long-term information related to kidney recovery following postsurgical AKI, given that follow-up for renal function recovery is almost nonexistent in recent clinical practice. Finally, while other investigators focused on the mortality issues in the specified surgical field having AKI, our results may provide data useful for generalized policy and practice frameworks for the proper perioperative care and future medical resource allocation.[@b46-clep-10-1583]

Conclusions
===========

As the public health and economic burdens of surgery-related complications continue to grow, recognizing the entity of outpatient target-organ dysfunction is critical. Outpatient dialysis dependency is a pivotal clinical entity of postsurgical complications. In this nationwide population cohort of 106,573 surgical patients with AKI-D, we demonstrated an independent association between AKI-D and in-hospital, 30-day, and long-term mortality risk. Furthermore, CTS patients who have a high incidence of AKI-D have a lower risk of in-hospital, 30-day, and long-term mortality. Nonetheless, patients with CTS-related AKI-D had a higher risk of 30-day dialysis dependency, although their potential for long-term dialysis dependence was similar to that of patients with non-CTS AKI-D. In an era of increasing focus on patient-centered care, as well as continued reimbursement and quality improvement pressure, increased consideration for the management of renal function recovery toward an optimal team-based coordinated care after postsurgical AKI as an outpatient is warranted. The appropriate transition of patients undergoing surgery to follow-up in the outpatient setting with an emphasis on the renal function recovery and mitigation of mortality risk is justifiable in enhancing the care of the high-risk patients undergoing major surgeries. Physicians and policymakers should be aware of these results to access possible benefits of earlier initiation of recovery pathways and identify how to effectively reduce mortality and dialysis dependence for better perioperative management and thereby improve quality and reduce costs.

Supplementary materials
=======================

###### 

The trend of yearly AKI-D incidence in 106,573 surgical patients and an annually adjusted hazard ratio of 30-day and long-term mortality in 1,861 surgical AKI-D patients, stratified by the surgical type.

**Notes:** The annual incidence of AKI-D was shown in (**A**) and was compared in different surgical types in (**B**). The adjusted hazard ratio of 30-day mortality of surgical AKI-D patients was shown in (**C**) and was compared in different surgical types in (**D**), while the adjusted hazard ratio of long-term mortality of surgical AKI-D patients was shown in (**E**) and was compared in different surgical types in (**F**). The incidence of AKI-D increased from 1.16% in 2001 to 1.75% in 2007 (trend *P*≤0.001) (Figure S1A). The adjusted hazard ratio for 30-day mortality increased from 7.7 (95% CI 6.35--9.35) in 2001 to 9.19 (95% CI 7.82--10.9) in 2007 (Figure S1C), and long-term mortality increased from 7.2 (95% CI 6.12--8.48) in 2001 to 10.04 (95% CI 8.69--11.61) in 2007 (Figure S1E). Post-CTS patients had a higher incidence of AKI-D compared with non-CTS patients (Figure S1B). However, the 30-day and long-term mortality were higher in non-CTS patients (Figure S1D and F). \*\**P*\<0·001.

**Abbreviations:** AKI-D, acute kidney injury requiring dialysis; CTS, cardiothoracic surgery.

###### 

The standardized mean difference (SMD) of the variables before and after the propensity score matching. After the matching, the SMD of all variables was \<0.1.

**Abbreviations:** CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ECMO, extracorporeal membrane oxygenation; GI, gastrointestinal.

###### 

Factors identified as predictors of AKI-D during index admission for the propensity score matching[a](#tfn10-clep-10-1583){ref-type="table-fn"}

  Predictive variables                    Odds ratio (95% CI)       *P*-value
  --------------------------------------- ------------------------- ------------------------------------------------------
  Advanced CKD                            32.740 (20.191--53.509)   \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Cardiac arrest                          5.115 (1.966--12.221)     \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Use of ECMO                             4.993 (4.236--5.890)      \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Acute respiratory distress syndrome     4.860 (4.240--5.567)      \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Hypovolemic shock                       3.472 (2.944--4.083)      \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Hospital stay length                    3.320 (2.961--3.722)      \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Repeat intubation                       1.733 (1.123--2.622)      0.011[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Chest tube insertion                    1.691 (1.443--1.976)      \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Severe sepsis                           1.624 (1.341--1.963)      \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Rheumatologic disease                   1.621 (1.023--2.466)      0.031[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Hemopericardium                         1.449 (0.973--2.099)      0.058
  Prolonged mechanical ventilation        1.397 (1.254--1.556)      \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  GI bleeding                             1.382 (1.120--1.694)      0.002[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Charlson comorbidity index score        1.307 (1.235--1.383)      \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Diabetes                                1.279 (1.112--1.471)      0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Surgical type (CVS vs others)           1.200 (1.034--1.389)      0.016[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Sex                                     1.101 (0.989--1.226)      0.079
  Age                                     1.009 (1.005--1.012)      \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Pneumonia                               0.832 (0.692--0.998)      0.049[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Pleural effusion                        0.734 (0.560--0.950)      0.022[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Myocardial infarction                   0.693 (0.539--0.884)      0.004[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Atrial fibrillation                     0.687 (0.530--0.879)      0.004[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Cerebrovascular disease                 0.623 (0.502--0.767)      \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Chronic obstructive pulmonary disease   0.563 (0.474--0.666)      \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Dementia                                0.557 (0.373--0.806)      0.003[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Hemiplegia or paraplegia                0.330 (0.135--0.698)      0.007[b](#tfn11-clep-10-1583){ref-type="table-fn"}
  Malignancy                              0.328 (0.236--0.452)      \<0.001[b](#tfn11-clep-10-1583){ref-type="table-fn"}

**Notes:**

Goodness of fit test: variance inflation faction of all factors (all \<2); adjust generalized *R*^2^=0.295; area under the receiver operating characteristic curve=0.906 (0.899--0.913); this model does not pass the modified Hosmer--Lemeshow test.

*P*\<0.05.

**Abbreviations:** AKI-D, acute kidney injury requiring dialysis; CKD, chronic kidney disease; CVS, cardiovascular surgery; ECMO, extra-corporeal membrane oxygenation; GI, gastrointestinal.

###### 

Incidence of AKI-D and its related crude mortality in 106,573 surgical patients stratified by four major surgeries

  Patients                    Surgery type     2001          2002          2003          2004          2005          2006          2007          Total          *P* for trend
  --------------------------- ---------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------- ---------------
  Patient numbers             All              14,424        14,886        13,615        15,328        15,775        16,212        16,333        106,573        
                              Cardiothoracic   2,037         2,120         1,937         2,969         3,738         3,753         3,781         20,335         
                              Esophagus        2,964         3,123         2,909         2,663         2,315         2,194         2,100         18,268         
                              Intestine        3,644         3,962         3,700         3,920         4,082         4,142         4,207         27,657         
                              Liver            5,779         5,681         5,069         5,776         5,640         6,123         6,245         40,313         
  AKI-D, n (%)                All              167 (1.16)    196 (1.32)    194 (1.43)    249 (1.62)    344 (2.18)    376 (2.32)    335 (2.05)    1,861 (1.75)   
                              Cardiothoracic   30 (1.47)     60 (2.83)     50 (2.58)     120 (4.04)    188 (5.03)    212 (5.65)    199 (5.26)    859 (4.22)     \<0.001
                              Esophagus        53 (1.79)     43 (1.38)     57 (1.96)     37 (1.39)     55 (2.38)     58 (2.64)     44 (2.10)     347 (1.90)     0.008
                              Intestine        54 (1.48)     61 (1.54)     56 (1.51)     54 (1.38)     53 (1.30)     73 (1.76)     53 (1.26)     404 (1.46)     0.661
                              Liver            30 (0.52)     32 (0.56)     31 (0.61)     38 (0.66)     48 (0.85)     33 (0.54)     39 (0.62)     251 (0.62)     0.378
  Mortality in AKI-D, n (%)   All              133 (79.64)   132 (67.35)   134 (69.07)   161 (64.66)   224 (65.12)   244 (64.89)   218 (65.07)   1246 (66.95)   
                              Cardiothoracic   22 (73.33)    30 (50.00)    30 (60.00)    70 (58.33)    110 (58.51)   122 (57.55)   116 (58.29)   500 (58.21)    0.789
                              Esophagus        46 (86.79)    33 (76.74)    46 (80.70)    27 (72.97)    46 (83.64)    49 (84.48)    37 (84.09)    284 (81.84)    0.771
                              Intestine        43 (79.63)    44 (72.13)    38 (67.86)    37 (68.52)    37 (69.81)    49 (67.12)    39 (73.58)    287 (71.04)    0.385
                              Liver            22 (73.33)    25 (78.13)    20 (64.52)    27 (71.05)    31 (64.58)    24 (72.73)    26 (66.67)    175 (79.72)    0.435

**Abbreviation:** AKI-D, acute kidney injury requiring dialysis.

###### 

The risk factors of short- and long-term mortality in surgical patients

  Risk factors                          Short-term mortality   Long-term mortality            
  ------------------------------------- ---------------------- --------------------- -------- -------------------
  AKI-D                                 1.7638                 5.83 (5.38--6.32)     1.2845   3.61 (3.37--3.87)
  Acute respiratory distress syndrome   1.2702                 3.56 (3.17--4.00)     1.0597   2.89 (2.64--3.16)
  Repeat intubation                     1.1378                 3.12 (2.48--3.92)     0.6363   1.89 (1.54--2.31)
  Hypovolemic shock                     0.932                  2.54 (2.27--2.84)     0.7595   2.14 (1.95--2.34)
  Chest tube insertion                  0.4487                 1.57 (1.40--1.75)     0.2963   1.34 (1.23--1.47)
  Stroke                                0.3789                 1.46 (1.16--1.83)     0.3096   1.36 (1.15--1.62)
  Hemopericardium                       0.3428                 1.41 (1.08--1.84)     --       
  GI bleeding                           0.1861                 1.20 (1.06--1.37)     --       
  Severe sepsis                         0.1387                 1.15 (1.04--1.26)     --       
  Rheumatologic disease                 --                                           0.2498   1.28 (1.00--1.64)
  Charlson comorbidity index score      0.1399                 1.15 (1.13--1.18)     0.1365   1.15 (1.12--1.18)
  Malignancy                            --                                           0.1681   1.18 (1.02--1.37)
  Liver disease                         --                                           0.1105   1.12 (1.00--1.24)
  Sex                                   0.091                  1.10 (1.01--1.19)     0.105    1.11 (1.04--1.18)
  Age                                   0.0142                 1.01 (1.01--1.02)     0.0205   1.02 (1.02--1.02)

**Abbreviations:** --, not applicable; AKI-D, acute kidney injury requiring dialysis; GI, gastrointestinal.

###### 

CTS and non-CTS patients matched

  The matched parameters             CTS n=79      Non-CTS n=154   SMD     Propensity score-matched                 
  ---------------------------------- ------------- --------------- ------- -------------------------- ------------- -------
  Male sex                           51 (64.56%)   109 (70.78%)    0.063   48 (66.67%)                47 (65.28%)   0.029
  Age                                66.36±14.59   65.41±15.75     0.133   65.50±14.59                66.89±15.21   0.093
  Charlson comorbidity index score   6.20±3.04     6.31±3.20       0.033   6.14±3.10                  6.24±3.22     0.031
  APACHE II score                    21.81±7.61    23.01±6.31      0.171   21.86±7.89                 22.14±6.38    0.039
  SOFA score                         12.53±3.96    12.31±3.92      0.056   12.29±3.87                 12.25±3.55    0.011

**Note:** Data presented as n (%) or mean ± SD.

**Abbreviations:** APACHE II, acute physiology and chronic health evaluation II; CTS, cardiothoracic surgery; SMD, standardized mean difference; SOFA, sequential organ failure assessment.
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**Abbreviations:** AKI, acute kidney injury; AKI-D, acute kidney injury requiring dialysis; AVF, arteriovenous fistula; ESRD, end-stage renal disease; RRT, renal replacement therapy.](clep-10-1583Fig1){#f1-clep-10-1583}

![The mortality and competing risks regression of cumulative subhazard for dialysis dependence among different surgeries in 8,320 propensity score-matched surgical patients.\
**Notes:** The hazard of short- and long-term mortality in different surgeries was shown in (**A**) and (**B**). The subhazard of short- and long-term dialysis dependence was shown in (**C**) and (**D**), while taking mortality as a competing risk.\
**Abbreviation:** CTS, cardiothoracic surgery.](clep-10-1583Fig2){#f2-clep-10-1583}

###### 

Basic demographic characteristics, comorbidities, complications, and outcomes in surgical patients stratified by AKI-D during the hospital stay

  Characteristic                                     All n=106,573     AKI-D n=1,861    Non-AKI-D n=104,712   SMD      Propensity score-matched                    
  -------------------------------------------------- ----------------- ---------------- --------------------- -------- -------------------------- ---------------- --------
  **Male sex**                                       60,847 (57.09%)   1,200 (64.48%)   59,647 (56.96%)       0.154    1,075 (64.60%)             4,440 (66.71%)   −0.044
  **Age at admission**                               58.72±16.88       65.91±15.33      58.59±16.88           −0.454   65.67±15.62                66.56±14.71      0.058
  **Surgical type**                                                                                                                                                
   Cardiothoracic                                    20,335 (19.08%)   859 (46.15%)     19,476 (18.60%)       −0.276   723 (43.45%)               3,033 (45.57%)   0.021
   Esophagus                                         18,268 (17.14%)   347 (18.65%)     17,921 (17.11%)       −0.026   331 (19.89%)               1,239 (18.61%)   −0.021
   Intestine                                         27,657 (25.95%)   404 (21.71%)     27,253 (26.03%)       0.077    372 (22.36%)               1,329 (19.97%)   −0.043
   Liver                                             40,313 (37.83%)   251 (13.49%)     40,062 (38.26%)       0.575    238 (14.30%)               1,055 (15.85%)   0.042
  **Comorbidities (before admission)**                                                                                                                             
   Myocardial infarction                             1,658 (1.56%)     119 (6.39%)      1,539 (1.47%)         0.255    95 (5.71%)                 394 (5.92%)      −0.009
   Congestive heart failure                          3,678 (3.45%)     283 (15.21%)     3,395 (3.24%)         0.423    226 (13.58%)               835 (12.55%)     0.031
   Peripheral vascular disease                       807 (0.76%)       35 (1.88%)       772 (0.74%)           0.101    29 (1.74%)                 166 (2.49%)      −0.052
   Cerebrovascular disease                           4,984 (4.68%)     141 (7.58%)      4,843 (4.63%)         0.124    119 (7.15%)                506 (7.60%)      −0.017
   Dementia                                          1,074 (1.01%)     34 (1.83%)       1,040 (0.99%)         0.071    32 (1.92%)                 155 (2.33%)      −0.028
   COPD                                              9,318 (8.74%)     244 (13.11%)     9,074 (8.67%)         0.143    219 (13.16%)               929 (13.96%)     −0.023
   Rheumatologic disease                             612 (8.74%)       27 (13.11%)      585 (8.67%)           0.090    21 (1.26%)                 96 (1.44%)       −0.016
   Peptic ulcer disease                              18,919 (17.75%)   326 (17.52%)     18,593 (17.76%)       −0.006   289 (17.37%)               1,166 (17.52%)   −0.004
   Mild liver disease                                8,185 (7.68%)     175 (9.40%)      8,010 (7.65%)         0.063    153 (9.19%)                612 (9.19%)      0.000
   Diabetes                                          14,127 (13.26%)   546 (29.34%)     13,581 (12.97%)       0.409    452 (27.16%)               1965 (29.52%)    −0.052
   Hemiplegia or paraplegia                          409 (0.38%)       8 (0.43%)        401 (0.38%)           0.007    6 (0.36%)                  28 (0.42%)       −0.010
   Malignancy                                        4,405 (4.13%)     80 (4.30%)       4,325 (4.13%)         0.008    76 (4.57%)                 275 (4.13%)      0.021
   Moderate or severe liver disease                  897 (0.84%)       54 (2.90%)       843 (0.81%)           0.156    49 (2.94%)                 176 (2.64%)      0.018
   AIDS                                              15 (0.01%)        0 (0.00%)        15 (0.01%)            −0.017   0 (0.00%)                  3 (0.05%)        −0.030
   Charlson comorbidity index score                  0.89±1.39         1.74±1.81        0.88±1.37             −0.537   1.59±1.72                  1.69±1.87        0.057
   CKD                                               1,197 (1.12%)     218 (11.71%)     979 (0.93%)           0.454    130 (7.81%)                447 (6.72%)      0.042
  **Comorbidities (during index hospitalization)**                                                                                                                 
   **Pulmonary complications**                                                                                                                                     
    Reintubation                                     157 (0.14%)       40 (2.15%)       117 (0.11%)           0.194    29 (1.74%)                 87 (1.31%)       0.036
    Acute respiratory distress syndrome              4,402 (4.13%)     738 (39.66%)     3,664 (3.50%)         0.979    603 (36.24%)               2,241 (33.67%)   0.054
    Pleural effusion                                 1,927 (1.81%)     78 (4.19%)       1,849 (1.77%)         0.143    71 (4.27%)                 298 (4.48%)      −0.010
    Chest tube insertion                             3,536 (3.32%)     315 (16.93%)     3,221 (3.08%)         0.474    253 (15.20%)               952 (14.30%)     0.025
   **Cardiac complications**                                                                                                                                       
    Hemopericardium                                  693 (0.65%)       37 (1.99%)       656 (0.63%)           0.120    33 (1.98%)                 144 (2.16%)      −0.013
    Hypovolemic shock                                2,277 (2.14%)     268 (14.40%)     2,009 (1.92%)         0.468    223 (13.40%)               831 (12.48%)     0.027
    Cardiac arrest                                   51 (0.05%)        9 (0.48%)        42 (0.04%)            0.087    7 (0.42%)                  16 (0.24%)       0.031
    Heart block                                      274 (0.26%)       11 (0.59%)       263 (0.25%)           0.053    8 (0.48%)                  31 (0.47%)       0.002
    Atrial fibrillation                              2,984 (2.80%)     92 (4.94%)       2,892 (2.76%)         0.114    81 (4.87%)                 355 (5.33%)      −0.021
    ECMO                                             5,050 (4.74%)     509 (27.35%)     4,541 (4.34%)         0.664    414 (24.88%)               1,692 (25.42%)   −0.012
   **Infectious complications**                                                                                                                                    
    Pneumonia                                        4,377 (4.11%)     355 (19.08%)     4,022 (3.84%)         0.493    293 (17.61%)               1,150 (17.28%)   0.009
    Urinary tract infection                          2,504 (2.35%)     100 (5.37%)      2,404 (2.30%)         0.161    80 (4.81%)                 386 (5.80%)      −0.044
    Severe sepsis                                    2,533 (2.38%)     387 (20.80%)     2,146 (2.05%)         0.617    319 (19.17%)               1,220 (18.33%)   0.022
   **Others**                                                                                                                                                      
    Delirium                                         180 (0.17%)       5 (0.27%)        175 (0.17%)           0.022    5 (0.30%)                  22 (0.33%)       −0.005
    Stroke                                           1,198 (1.12%)     48 (2.58%)       1,150 (1.10%)         0.110    39 (2.34%)                 157 (2.36%)      −0.001
    GI bleeding                                      2,733 (2.56%)     142 (7.63%)      2,591 (2.47%)         0.237    123 (7.39%)                515 (7.74%)      −0.013

**Note:** Data presented as n (%) or mean ± SD.

**Abbreviations:** AKI-D, acute kidney injury requiring dialysis; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ECMO, extracorporeal membrane oxygenation; GI, gastrointestinal; SMD, standardized mean difference.

###### 

Comparison of the in-hospital, 30-day, and long-term mortality in AKI-D vs non-AKI-D in surgical patients before and after propensity score matching[a](#tfn3-clep-10-1583){ref-type="table-fn"}

                    Mortality     Events      Person- years   Incidence (per 1,000 person-years)   Events          Person- years   Incidence (per 1,000 person-years)   Crude hazard ratio (95% CI)   Adjust hazard ratio[b](#tfn4-clep-10-1583){ref-type="table-fn"} (95% CI)
  ----------------- ------------- ----------- --------------- ------------------------------------ --------------- --------------- ------------------------------------ ----------------------------- --------------------------------------------------------------------------
                                  **AKI-D**                                                        **Non-AKI-D**                                                                                      
                                                                                                                                                                                                      
  Before matching   In-hospital   1,084       90,201          12                                   4,066           1,707,808       2.4                                  3.64 (3.39--3.91)             3.37 (3.13--3.62)
  30-day            1,246         109,626     11.4            5,616                                4,698,184       1.2             7.63 (7.13--8.16)                    6.03 (5.64--6.45)             
  Long-term         1,439         503,341     2.9             24,197                               104,893,286     02              8.72 (8.26--9.20)                    5.79 (5.48--6.11)             
                                                                                                                                                                                                      
                                  **AKI-D**                                                        **Non-AKI-D**                                                                                      
                                                                                                                                                                                                      
  After matching    In-hospital   1,006       74,417          13.5                                 1,161           256,992         4.5                                  3.00 (2.76--3.27)             3.04 (2.79--3.31)
  30-day            1,146         90,744      12.6            1,507                                415,220         3.6             3.58 (3.31--3.87)                    3.65 (3.37--3.94)             
  Long-term         1,300         436,476     3               3,065                                4,179,988       0.7             3.08 (2.88--3.29)                    3.22 (3.01--3.44)             

**Notes:**

This model showed good validity, with the adjusted generalized *R*^2^ and the concordance index being 0.4142 and 0.86, respectively.

Adjusted by age, sex, surgery type, Charlson comorbidity index, and individual comorbidities.

**Abbreviation:** AKI-D, acute kidney injury requiring dialysis.

###### 

Comparison of the in-hospital, 30-day, and long-term mortality and dialysis dependence in AKI-D patients undergoing CTS vs non-CTS before and after propensity score matching

             Outcome                       Events    Person-years   Incidence (per 1,000 person-years)   Events        Person- years   Incidence (per 1,000 person-years)   Crude hazard ratio (95% CI)   Adjust hazard ratio[a](#tfn6-clep-10-1583){ref-type="table-fn"} (95% CI)   Compete subhazard ratio (95% CI)
  ---------- ----------------------------- --------- -------------- ------------------------------------ ------------- --------------- ------------------------------------ ----------------------------- -------------------------------------------------------------------------- ----------------------------------
                                           **CTS**                                                       **Non-CTS**                                                                                                                                                                 
                                                                                                                                                                                                                                                                                     
  Before     In-hospital mortality         435       42,204         10.3                                 649           47,997          13.5                                 0.77 (0.68--0.87)             0.79 (0.70--0.89)                                                          NA
  matching   30-day dialysis               98        50,940         1.9                                  76            54,404          1.4                                  1·33 (0.99--1.80)             1.29 (0.95--1.75)                                                          1.53 (1.13--2.08)
             30-day mortality              500       53,395         9.4                                  746           56,231          13.3                                 0.72 (0.65--0.81)             0.74 (0.66--0.83)                                                          NA
             30-day composite outcome      595       50,940         11.7                                 818           54,404          15                                   0.79 (0.71--0.88)             0.80 (0.72--0.89)                                                          NA
             Long-term dialysis            85        204,271        0.4                                  75            185,973         0.4                                  1.07 (0.78--1.46)             0.99 (0.72--1.36)                                                          1.28 (0.93--1.75)
             Long-term mortality           605       258,081        2.3                                  834           245,260         3.4                                  0.74 (0.67--0.82)             0.77 (0.69--0.86)                                                          NA
             Long-term composite outcome   661       204,271        3.2                                  885           185,973         4.8                                  0.76 (0.68--0.84)             0.78 (0.70--0.86)                                                          NA
                                                                                                                                                                                                                                                                                     
                                           **CTS**                                                       **Non-CTS**                                                                                                                                                                 
                                                                                                                                                                                                                                                                                     
  After      In-hospital mortality         380       31,598         12                                   626           42,819          14.6                                 0.84 (0.74--0.95)             0.85 (0.75--0.97)                                                          NA
  matching   30-day dialysis               72        38,732         1.9                                  59            48,684          1.2                                  1.51 (1.07--2.13)             1.49 (1.05--2.11)                                                          1.67 (1.18--2.38)
             30-day mortality              433       40,590         10.7                                 713           50,154          14.2                                 0.77 (0.69--0.87)             0.79 (0.70--0.89)                                                          NA
             30-day composite outcome      503       38,732         13                                   769           48,684          15.8                                 0.84 (0.75--0.94)             0.85 (0.76--0.96)                                                          NA
             Long-term dialysis            62        174,374        0.4                                  58            176,277         0.3                                  1.15 (0.80--1.64)             1.10 (0.77--1.59)                                                          1.38 (0.96--2.00)
             Long-term mortality           512       211,117        2.4                                  788           225,359         3.5                                  0.77 (0.69--0.86)             0.80 (0.72--0.90)                                                          NA
             Long-term composite outcome   551       174,374        3.2                                  828           176,277         4.7                                  0.79 (0.70--0.87)             0.81 (0.73--0.91)                                                          NA

**Notes:**

Adjusted by age, sex, Charlson comorbidity index, and individual comorbidities.

**Abbreviations:** CTS, cardiothoracic surgery; NA, not applicable.

###### 

The comparison between CTS and non-CTS patients after propensity score matching in NEP-AKI-D study[@b23-clep-10-1583] database

                                                        CTS n=79             Non-CTS n=154        SMD     Propensity score-matched                        
  ----------------------------------------------------- -------------------- -------------------- ------- -------------------------- -------------------- -------
  **Comorbidities (during index hospitalization)**                                                                                                        
   Sepsis                                               40 (50.63%)          129 (83.77%)         0.750   36 (50.00%)                62 (86.11%)          0.834
   Azotemia                                             26 (32.91%)          78 (50.65%)          0.364   22 (30.56%)                35 (48.61%)          0.402
   Fluid overload                                       54 (68.35%)          113 (73.38%)         0.110   48 (66.67%)                52 (72.22%)          0.089
   Electrolyte imbalance                                25 (31.65%)          47 (30.52%)          0.024   22 (30.56%)                21 (29.17%)          0.030
   Acid--base imbalance                                 26 (32.91%)          74 (48.05%)          0.311   25 (34.72%)                31 (43.06%)          0.170
   Uremia                                               3 (3.80%)            6 (3.90%)            0.005   3 (4.17%)                  2 (2.78%)            0.075
   Oliguria                                             55 (69.62%)          109 (70.78%)         0.002   52 (72.22%)                57 (79.17%)          0.128
  **Laboratory data**                                                                                                                                     
   **At initiation of RRT**                                                                                                                               
    Glasgow coma scale                                  8.63±4.22            8.31±3.90            0.079   8.65±4.36                  8.32±3.78            0.108
    PaO~2~/FiO~2~                                       272.49±180.28        295.34±190.09        0.123   281.89±184.93              296.17±196.90        0.122
    Mean arterial pressure                              80.59±17.96          82.16±21.17          0.080   80.38±18.64                81.20±22.18          0.065
    Serum PH                                            7.37±0.11            7.34±0.12            0.261   7.37±0.11                  7.36±0.12            0.089
    Serum HCO~3~                                        20.60±5.06           17.74±6.18           0.507   20.41±5.16                 18.20±5.20           0.403
    Albumin                                             2.95±0.65            2.58±0.66            1.123   2.96±0.67                  2.64±0.72            1.382
    Total bilirubin                                     2.19±3.70            3.38±6.65            0.220   2.25±3.86                  3.37±5.83            0.229
    Aspartate aminotransferase                          457.30±1,227.30      593.83±1,625.58      2.535   473.88±1,277.13            429.89±1,009.50      2.626
    Na                                                  142.57±7.53          139.72±8.41          0.357   142.48±7.65                139.04±8.16          0.405
    K                                                   4.42±0.97            4.62±1.08            0.193   4.45±0.95                  4.62±1.01            0.131
    White blood cell count                              12,777.22±6,311.08   14,052.93±8,926.50   0.165   12,990.97±6,397.34         14,055.69±8,219.88   0.137
    Blood urine nitrogen                                62.50±43.55          79.56±45.49          0.383   61.17±44.46                78.17±41.37          0.408
    Creatinine                                          3.53±2.04            5.04±2.94            0.597   3.44±1.77                  4.92±2.28            0.700
    Urine output                                        547.44±671.81        504.50±872.12        0.055   536.08±683.60              417.81±561.45        0.115
    Lactic acid                                         5.35±4.95            5.90±6.31            1.749   4.64±4.68                  5.78±7.13            1.703
   **RRT modalities**                                                                             0.260                                                   0.334
    CVVH                                                42 (85.71%)          48 (31.17%)                  37 (51.39%)                18 (25.00%)          
    SLEDD/SLEDD-f                                       4 (5.06%)            7 (4.55%)                    4 (5.56%)                  5 (6.94%)            
    IHD                                                 26 (32.91%)          84 (54.55%)                  24 (33.33%)                40 (55.56%)          
    Mix methods                                         7 (8.86%)            15 (9.74%)                   7 (9.72%)                  9 (12.50%)           
  **Hospital stay length**                              42.20±35.57          44.13±34.78          0.055   41.51±36.15                45.58±36.98          0.127
  **Short-term mortality**                              42 (53.16%)          93 (60.39%)          0.146   37 (51.39%)                43 (59.72%)          0.139
  **Long-term mortality**                               46 (58.23%)          104 (67.53%)         0.193   41 (56.94%)                48 (66.67%)          0.170
  **Long-term survival with renal function recovery**   26 (32.91%)          38 (24.68%)          0.182   25 (34.72%)                16 (22.22%)          0.245

**Note:** Data presented as n (%) or mean ± SD.

**Abbreviations:** CTS, cardiothoracic surgery; CVVH, continuous venovenous hemofiltration; IHD, intermittent hemodialysis; NEP-AKI-D, nationwide epidemiology and prognosis of dialysis-requiring acute kidney injury; non-CTS, noncardiothoracic surgery; RRT, renal replacement therapy; SLEDD, sustained low-efficiency daily dialysis; SLEDD-f, sustained low-efficiency daily diafiltration; SMD, standardized mean difference.
